Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 28 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 28 Mar 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.
- 28 Mar 2019 Status changed from recruiting to active, no longer recruiting.